Adjuvant Therapy Using Dabrafenib plus Trametinib in Chinese Patients with Resected Stage III Melanoma: A Multicenter Retrospective Cohort Study

Table 2

Safety profile of adjuvant dabrafenib plus trametinib.

Adverse event	Any grade	Grade 3 or 4
Any adverse event	38 (69.1%)	17 (30.9%)
Pyrexia	31 (56.4%)	13 (23.6%)
Fatigue	17 (30.9%)	4 (7.3%)
Nausea	15 (27.3%)	3 (5.5%)
Headache	14 (25.5%)	3 (5.5%)
Chills	12 (21.8%)	2 (3.6%)
Diarrhea	11 (20%)	2 (3.6%)
Rash	10 (18.2%)	1 (1.8%)
Vomiting	9 (16.4%)	1 (1.8%)
Arthralgia	8 (14.5%)	0
Panniculitis	8 (14.5%)	0
Cough	8 (14.5%)	0
Elevated alanine aminotransferase	7 (12.7%)	0
Elevated aspartate aminotransferase	6 (10.9%)	0
Peripheral edema	5 (9.1%)	0
Constipation	5 (9.1%)	0
Hypertension	2 (3.6%)	0
Decreased appetite	1 (1.8%)	0
Erythema	1 (1.8%)	0